Table 2.

Clinical parameters in SHIV-infected Chinese RM

Animal no.	Age (Year)*	Gender	Inoculation**	SHIV strains	Dose AID50/TCID50***	Peak viral load in plasma	Survival time (weeks)****	Ref
2	3.5–4.5	mixed	I.R.	89.6P	40 AID50	8 × 105–7 × 106	>24W	[41]
10	6.1–7.1	NP	I.V.	89.6P	103AID50	1 × 107	>36W	[42]
6	4–5	NP	I.V.	89.6P	20 AID50	~2 × 105–3 × 106	>40W (5/6)	[43]
6	4–8	NP	I.V.	89.6P	103 AID50	NP	NP	[44]
6	NP	F	IVAG (13 times)	SF162P3	20, 30 TCID50	6.3 × 105–1.6 × 107	>29W	[45]
8	3–5	F	I.V.	SF162P4	18 AID50	1.6 × 105–2.5 × 106	>10W	[46]
8	5–6	F	I.V.	SF162P4	22 TCID50	1.6 × 105–3.2 × 106	>10W	[47]
12	3.5–7	F	IVAG (6 times)	SF162P3	3 × 102 TCID50	1.1 × 106–3.5 × 106	N/P	[48]
4	Adult	M	I.R.	SF162P3	10 TCID50	~106–107	>32W	[49]
10	5–15	F	IVAG	SF162P3	3 × 102 TCID50	3.2 × 105–1 × 108	≥10W	[50]
8	NP	7M/1F	I.R. (M) IVAG (F)	SF162p3	10 TCID50	NP	NP	[51]
4	8.09 (mean)	NP	I.R.	RT	103 TCID50	1 × 104–2 × 106	>20W	[52]
2					104 TCID50	5 × 105–2 × 107	>16W
5	Adult	F	IVAG	RT	103 TCID50	2 × 106–2 × 107	>20W	[53]
2					2 × 102 TCID50	1 × 106 (1/2)	>20W
16	4–12	F	IVAG	RT	103 TCID50	105–107 (9/16)	>16W	[54]
30						~4 × 104–6 × 107 (22/30)

^*NP: The information is not provided in the paper;

^**I.R.: intrarectally; I.V.: intravenously; IVAG: intravaginally;

^***TCID₅₀: 50% tissue culture infective dose; AID₅₀ : 50% animal infectious doses; Viral titer was quantified in different cells;

^****W: Weeks; M: Months.